Literature DB >> 22799338

Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells.

Dong-Dong Cheng1, Qing-Cheng Yang, Zhi-Chang Zhang, Cui-Xia Yang, Yi-Wen Liu.   

Abstract

BACKGROUND: Histone deacetylase (HDAC) inhibitors have been reported to induce cell growth arrest, apoptosis and differentiation of tumor cells. The present study aimed to examine the effects of trichostatin A (TSA), one such inhibitor, on the cell cycle, apoptosis and invasiveness of osteosarcoma cells.
METHODS: MG- 63 cells were treated with TSA at various concentrations. Then, cell growth and apoptosis were determined by 3-(4, 5-dimethyl-2-thiazolyl)-2H-tetrazolium bromide (MTT) and TUNEL assays, respectively; cell cycling was assessed by flow cytometry; invasion assays were performed with the transwell Boyden Chamber system.
RESULTS: MTT assays revealed that TSA significantly inhibited the growth of MG-63 cells in a concentration and time dependent manner. TSA treated cells demonstrated morphological changes indicative of apoptosis and TUNEL assays revealed increased apoptosis of MG-63 cells after TSA treatment. Flow cytometry showed that TSA arrested the cell cycle in G1/G2 phase and annexin V positive apoptotic cells increased markedly. In addition, the invasiveness of MG-63 cells was inhibited by TSA in a concentration dependent manner.
CONCLUSION: Our findings demonstrate that TSA inhibits the proliferation, induces apoptosis and inhibits invasiveness of osteosarcoma cells in vitro. HDAC inhibitors may thus have promise to become new therapeutic agents against osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22799338     DOI: 10.7314/apjcp.2012.13.4.1395

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

1.  Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.

Authors:  Wei-Min Ruan; Yun-Long Li; Gang Nie; Wen-Xue Zhou; Xiao-Ming Zou
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

3.  Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.

Authors:  Sangsu Shin; Miok Kim; Seon-Jin Lee; Kang-Seo Park; Chang Hoon Lee
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

4.  Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.

Authors:  Xuan Zhang; Shu-Juan Jiang; Bin Shang; Hong-Juan Jiang
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

5.  Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.

Authors:  Zhantao Deng; Xiaozhou Liu; Jiewen Jin; Haidong Xu; Qian Gao; Yong Wang; Jianning Zhao
Journal:  Int J Biol Sci       Date:  2016-10-18       Impact factor: 6.580

6.  Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.

Authors:  Haydee M Torres; Ashley M VanCleave; Mykayla Vollmer; Dakota L Callahan; Austyn Smithback; Josephine M Conn; Tania Rodezno-Antunes; Zili Gao; Yuxia Cao; Yohannes Afeworki; Jianning Tao
Journal:  Cancers (Basel)       Date:  2021-08-20       Impact factor: 6.639

7.  Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells.

Authors:  Jason E Cain; Andrew McCaw; W Samantha N Jayasekara; Fernando J Rossello; Kieren D Marini; Aaron T Irving; Maya Kansara; David M Thomas; David M Ashley; D Neil Watkins
Journal:  Sarcoma       Date:  2013-02-28

8.  Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.

Authors:  María Díaz-Núñez; Alejandro Díez-Torre; Olivier De Wever; Ricardo Andrade; Jon Arluzea; Margarita Silió; Juan Aréchaga
Journal:  BMC Cancer       Date:  2016-08-22       Impact factor: 4.430

9.  MiR-542-5p is a negative prognostic factor and promotes osteosarcoma tumorigenesis by targeting HUWE1.

Authors:  Dong-dong Cheng; Tao Yu; Tu Hu; Ming Yao; Cun-yi Fan; Qing-cheng Yang
Journal:  Oncotarget       Date:  2015-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.